Abstract: Produced the gene therapy DNA vectors based on the gene therapy DNA vector for treatment of diseases associated with disorders of osteogenesis, formation and regeneration of bone and cartilage tissues, including, in case of bone fractures, increased brittleness of bones, reduction of bones mineralisation, for improvement in osteoinduction of bone implants. The gene therapy DNA vector contains the coding region of the COL1A1, COL1A2, BMP2 or BMP7 therapeutic genes. Methods of producing or use the gene therapy DNA vector carrying therapeutic genes. Escherichia coli strain SCS110-AF/VTvaf17-COL1A1, SCS110-AF/VTvaf17-COL1A2, SCS110-AF/VTvaf17-BMP2 or SCS110-AF/VTvaf17-BMP7 obtains by the method described above carrying gene therapy DNA vector VTvaf17-COL1A1, VTvaf17-COL1A2, VTvaf17-BMP2 or VTvaf17-BMP7. The method of producing the gene therapy DNA vector carrying COL1A1, or COL1A2, or BMP2, or BMP7 therapeutic gene uses on an industrial scale.

Abstract: Disclosed is a gene therapy DNA vector VTvaf17 for genetic modification of animal and human cells having SEQ ID No. 1, and methods for its synthesis, involving constructing vectors containing a promoter region of human elongation factor EF1A, a polylinker with sites for restriction endonucleases, a transcription terminator, a polyadenylation sequence of human growth factor, a regulatory element of transposon Tn10 allowing for antibiotic-free positive selection, an origin of replication, and a kanamycin resistance gene. Escherichia coli strain SCS110-AF is also provided by the present invention. The method for creating the strain involves constructing a linear DNA fragment containing regulatory element of transposon Tn10, a levansucrase gene, sacB, a chloramphenicol resistance gene, and two homologous sequences. The E. coli cells are transformed by electroporation and clones surviving chloramphenicol are chosen.